Ferguson Wellman Capital Management Inc. Has $58.85 Million Stock Position in Stryker Corporation $SYK

Ferguson Wellman Capital Management Inc. grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 186,935 shares of the medical technology company’s stock after purchasing an additional 2,180 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Stryker were worth $58,855,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Varma Mutual Pension Insurance Co increased its holdings in Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after acquiring an additional 5,100 shares during the last quarter. QRG Capital Management Inc. boosted its holdings in shares of Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after purchasing an additional 4,186 shares during the last quarter. Swedbank AB boosted its holdings in shares of Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after purchasing an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. grew its position in shares of Stryker by 31.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after purchasing an additional 6,367 shares in the last quarter. Finally, Royal Bank of Canada grew its position in shares of Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 2.9%

Shares of NYSE:SYK opened at $331.32 on Friday. The company has a market cap of $127.08 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 2.05 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $329.10 and a 200 day moving average price of $331.47.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Insider Activity at Stryker

In related news, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 351,267 shares of company stock worth $118,197,701. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of research analyst reports. Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Leerink Partners reduced their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Citigroup reaffirmed a “buy” rating on shares of Stryker in a report on Thursday, August 13th. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Finally, Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.